ADMA— ADMA BIOLOGICS, INC.

MaterialsBiotechnology$2.2B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
REVENUES	$510.2M+19.6%	$426.5M+65.2%	$258.2M+67.6%	$154.1M
Cost of product revenue	$217.4M+5.1%	$206.9M+22.2%	$169.3M+42.5%	$118.8M
Gross profit	$292.8M+33.3%	$219.6M+146.8%	$88.9M+152.2%	$35.3M
Research and development	$4.8M+162.7%	$1.8M-45.1%	$3.3M-8.7%	$3.6M
Plasma center operating expenses	$4.8M+13.9%	$4.2M-0.5%	$4.3M-76.1%	$17.8M
Amortization of intangible assets	$144K-62.9%	$388K-46.4%	$724K+1.3%	$715K
Selling, general and administrative	$91.6M+23.5%	$74.1M+25.6%	$59.0M+12.5%	$52.5M
Total operating expenses	$101.3M+25.8%	$80.6M+19.7%	$67.3M-9.8%	$74.6M
INCOME FROM OPERATIONS	$191.4M+37.7%	$139.0M+542.5%	$21.6M+155.0%	-$39.4M
Interest income	$1.9M-10.8%	$2.1M+29.7%	$1.6M+3493.3%	$45K
Interest expense	-$7.1M+49.0%	-$13.9M+44.3%	-$25.0M-29.8%	-$19.3M
Loss on extinguishment of debt	-$3.3M-168.4%	-$1.2M+95.3%	-$26.2M-292.4%	-$6.7M
Other expense	-$212K-9.8%	-$193K+32.8%	-$287K+54.8%	-$635K
Other expense, net	-$8.8M+33.8%	-$13.3M+73.4%	-$49.9M-87.9%	-$26.5M
INCOME (LOSS) BEFORE INCOME TAXES	$182.7M+45.3%	$125.7M+545.2%	-$28.2M+57.2%	-$65.9M
Income tax expense (benefit)	$35.7M+149.6%	-$72.0M	$0	$0
NET INCOME (LOSS)	$146.9M-25.7%	$197.7M+800.0%	-$28.2M+57.2%	-$65.9M
BASIC EARNINGS (LOSS) PER COMMON SHARE (in Dollars per share)	$620.00-27.1%	$850.00+753.8%	-$130.00+60.6%	-$330.00
DILUTED EARNINGS (LOSS) PER COMMON SHARE (in Dollars per share)	$600.00-25.9%	$810.00+723.1%	-$130.00+60.6%	-$330.00
Basic (in Shares)	238.30B+2.2%	233.08B+4.1%	223.98B+13.2%	197.87B
Diluted (in Shares)	244.90B+0.6%	243.34B+8.6%	223.98B+13.2%	197.87B

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.